Most Read Articles
5 days ago
Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.
2 days ago
Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs, reports a new Japan study.
17 Aug 2019
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.
6 days ago
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.

Recombinant thrombomodulin safely improves acute exacerbation in idiopathic interstitial pneumonias

12 Jul 2019
Smoking is one cause of idiopathic pulmonary fibrosis, apart from hereditary factors and inhalation of certain types of dust.

Recombinant human soluble thrombomodulin (rhTM) is a safe and effective treatment for acute exacerbation (AE) in other idiopathic interstitial pneumonias (IIP), a recent study has shown.

AE-IIP patients treated with rhTM had a 90-day survival rate of 66.7 percent (26/39), while those who were not treated with rhTM had a survival rate of 47.5 percent (29/61). After adjusting for imbalances, a significant association was found between rhTM therapy and reduced mortality (adjusted hazard ratio, 0.453, 95 percent CI, 0.237–0.864; p=0.0163).

Adverse events occurred in 17.9 percent (7/39) of patients treated with rhTM and in 19.7 percent (12/61) of those who did not receive rhTM, which were comparable in both groups (p=1.0). In addition, the rhTM group reported two cases of bleeding events.

Future randomized controlled trials are warranted to confirm these findings.

This prospective, single-arm, open-label, multicentre cohort study retrospectively registered 61 patients with AE-IIP who were treated with conventional therapy between 2011 and 2013 (control group) and prospectively included 39 patients with AE-IIP who received conventional therapy and rhTM (380 U/kg/day for 6 days) between 2014 and 2016 (rhTM group).

The investigators conducted an adjusted mortality analysis for 90-day survival with weighted Cox proportional regression models using inverse probability of treatment weighting to reduce potential confounding in treatment comparisons. Weights were derived from propensity score estimated using a multivariable logistic regression analysis, including potential confounders.

“AE in idiopathic pulmonary fibrosis or other IIP is a poor prognostic event despite conventional therapy with corticosteroids and/or immunosuppressants,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.
2 days ago
Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs, reports a new Japan study.
17 Aug 2019
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.
6 days ago
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.